Fruquintinib With mFOLFOX6/FOLFIRI as First-Line Therapy for Conversion Surgery in mCRC
The goal of this clinical trial is to learn about the efficacy and safety of Fruquintinib with mFOLFOX6/FOLFIRI in patients with mCRC. The main question it aims to answer is:

The conversion surgery rate of the therapy mentioned above. The ORR, R0 surgery rate, DCR, PFS, OS, and safety will be evaluated.
Colorectal Cancer
DRUG: Fruquintinib+mFOLFOX6/FOLFIRI
Objective Response Rate（ORR）, Objective Response Rate: The proportion of participants in the analyzed population who developed complete (CR) or partial response (PR) according to RECIST 1.1 criteria., through study completion, an average of 2 year
R0 Surgery Rate, R0 Surgery Rate: R0 corresponds to resection for cure or complete remission., through study completion, an average of 2 year|Disease Control Rate（DCR）, Disease Control Rate: The proportion of subjects in the analyzed population who achieved CR, PR, or stable disease (SD) according to RECIST 1.1 criteria., through study completion, an average of 2 year|Progression Free Survival（PFS）, Progression-Free Survival: Time from patient admission to first radiographic disease progression (RECIST 1.1 criteria) or death (whichever occurs first)., through study completion, an average of 2 year|Overall Survival（OS）, Overall Survival: From the time of patient admission to the time of subject's death, at the end of the study, if the subject is still alive, the last known date of subject's survival is the deletion date., through study completion, an average of 2 year
The goal of this clinical trial is to learn about the efficacy and safety of Fruquintinib with mFOLFOX6/FOLFIRI in patients with mCRC. The main question it aims to answer is:

The conversion surgery rate of the therapy mentioned above. The ORR, R0 surgery rate, DCR, PFS, OS, and safety will be evaluated.